SCHEMBL1290126

SCHEMBL1290126

Cc1c(-c2ccc(N)c(F)c2)ccn2c(=O)c(C(=O)O)cc(C3CC3)c12

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.34
CAMKK2 Q96RR4 4/20 0.33
CAMKK1 Q8N5S9 3/20 0.33
CD274 Q9NZQ7 1/20 0.32
MAPK13 O15264 1/20 0.32
KDM4C Q9H3R0 2/20 0.32
PIK3CA P42336 1/20 0.32
KDM4E B2RXH2 2/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
PKM P14618 1/20 0.31
DGAT1 O75907 1/20 0.31
RORC P51449 1/20 0.31
GFER P55789 1/20 0.31
KMT2A Q03164 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
SLC6A3 Q01959 1/20 0.31
SCN5A Q14524 1/20 0.31
TNK2 Q07912 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1290001 0.92 BRD4 (0.36) NOTUMCAMKK2CAMKK1CD274MAPK13
Potassium Ion SCHEMBL1290133 0.90 MAPK13 (0.31) MAPK13PIK3CA
SCHEMBL1290284 0.90 CAMKK2 (0.34) NOTUMCAMKK2CAMKK1KDM4EALDH1A1
SCHEMBL1290162 0.90 NOTUM (0.37) NOTUMCAMKK2CAMKK1CD274MAPK13
SCHEMBL1290167 0.90 SLC6A3 (0.37) MAPK13PIK3CAKDM4EALDH1A1GAA
SCHEMBL12502336 0.89 KDM4E (0.36) NOTUMCAMKK2CAMKK1MAPK13KDM4C
SCHEMBL1289936 0.89 RORC (0.35) NOTUMCAMKK2CAMKK1KDM4EALDH1A1
SCHEMBL19723472 0.88 CAMKK2 (0.35) NOTUMCAMKK2CAMKK1KDM4EALDH1A1
SCHEMBL5417688 0.88 CAMKK2 (0.35) NOTUMCAMKK2CAMKK1MAPK13KDM4E
SCHEMBL5421668 0.88 KDM4E (0.38) KDM4EALDH1A1GAAPKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10155021-B2 Antimicrobial 4-oxoquinolizines EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2018-12-18 US claimed
EP-2670410-B1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEV GAITHERSBURG INC (US) 2017-12-20 EP claimed
US-20170232060-A9 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2017-08-17 US claimed
US-20170106045-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2017-04-20 US claimed
US-20150141435-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2015-05-21 US claimed
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2013-09-19 US claimed
EP-2621491-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS Evolva SA (CH) 2013-08-07 EP claimed
WO-2012047487-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2012-04-12 WO claimed
EP-3476844-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Emergent Product Development Gaithersburg Inc. (US) 2019-05-01 EP disclosed
EP-3476844-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Emergent Product Development Gaithersburg Inc. (US) 2019-05-01 EP disclosed
US-20190105367-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2019-04-11 US disclosed
US-20190105367-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2019-04-11 US disclosed
US-10155021-B2 Antimicrobial 4-oxoquinolizines EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2018-12-18 US disclosed
US-20180296555-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2018-10-18 US disclosed
WO-2012104305-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EVOLVA SA (CH) 2012-08-09 WO disclosed
WO-2012047487-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2012-04-12 WO disclosed
WO-2012047487-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2012-04-12 WO disclosed
US-7223773-B2 4-oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SALO PHARMACEUTICAL CO., LTD. (JP) 2007-05-29 US disclosed
US-20040229903-A1 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SATO PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
EP-1437354-A1 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETON AS PARTIAL STRUCTURE Sato Pharmaceutical Co. Ltd. (JP) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190105367-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B NOTUM 3732/4885CAMKK2 4000/4885CAMKK1 4097/4885
US-10155021-B2 Antimicrobial 4-oxoquinolizines DCAF15, CUL4A, CUL4B NOTUM 3793/4885CAMKK2 3951/4885CAMKK1 4073/4885
US-20180296555-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B NOTUM 4787/4885CAMKK2 1101/4885CAMKK1 1100/4885
US-20170106045-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B NOTUM 3732/4885CAMKK2 4000/4885CAMKK1 4097/4885
US-20170232060-A9 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B NOTUM 3732/4885CAMKK2 4000/4885CAMKK1 4097/4885
US-20150141435-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B NOTUM 4787/4885CAMKK2 1101/4885CAMKK1 1100/4885
US-20040229903-A1 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SDHA, IL4I1, BLVRB NOTUM 4424/4885CAMKK2 2773/4885CAMKK1 2444/4885
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B NOTUM 4829/4885CAMKK2 1047/4885CAMKK1 1158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.